The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2016 | FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma

Name: FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma
Uploaded: 2016-06-03T00:00:00.000Z
Duration: 8 min 41 s
Description: Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

Salah-Eddin Al-Batran • 3 Jun 2016

ASCO 2016

Gastrointestinal Cancer

FAST

Press brief by Salah-Eddin Al-Batran, MD of the Krankenhaus Nordwest-University Cancer Center, Frankfurt, Germany, at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.